[Tree] Zai Lab's recent approvals for Augtyro and Vyvgart SC in China

Version 0.21 (2024-05-21 16:52:08.978000)

updates: Zai Lab's recent approvals for Augtyro and Vyvgart SC in China

  • ➔
Version 0.2 (2024-05-02 02:37:03.824000)

updates: Delhi High Court ruling on VIAGRA trademark

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.19 (2024-04-29 05:56:14.558000)

updates: Glenmark Pharmaceuticals receives USFDA approval for generic anti-inflammatory drug

  • ➔
  • ➔
  • ➔
  • ➔
Version 0.18 (2024-04-14 10:20:46.197000)

updates: Glenmark Pharmaceuticals recalls blood pressure drug in the US

  • ➔
  • ➔
  • ➔
Version 0.17 (2024-04-14 06:18:00.936000)

updates: Added information about the recall of Glenmark's blood pressure drug

  • ➔
  • ➔
  • ➔
Version 0.16 (2024-04-02 17:22:02.361000)

updates: The US FDA reports tight supply of Mounjaro diabetes drug

  • ➔
  • ➔
Version 0.15 (2023-10-31 15:38:58.144000)

updates: The narrative has been expanded and includes information about the trade complaint filed by Eli Lilly to block knock-offs of its weight-loss drug

  • ➔
Version 0.14 (2023-10-20 05:16:17.180000)

updates: The article provides information about Eli Lilly filing a trade complaint to block weight-loss drug knock-offs.

  • ➔
Version 0.13 (2023-10-15 14:51:06.939000)

updates: The new narrative provides a comprehensive overview of the impact of GLP-1 weight-loss drugs on the stock market, including information on the growth of drug manufacturers, supply shortages, advertising spending, and market analysis.

  • ➔
  • ➔
  • ➔
  • ➔
Version 0.12 (2023-10-14 09:34:47.612000)

updates: Incorporated information about the impact of GLP-1 weight-loss drugs on the stock market and the projected annual sales of GLP-1 drugs by 2030.

  • ➔
  • ➔
  • ➔
  • ➔
Version 0.11 (2023-10-08 16:02:28.504000)

updates: The new narrative incorporates information about the market for obesity medications and the impact of the COVID-19 pandemic.

  • ➔
  • ➔
  • ➔
Version 0.1 (2023-10-08 16:01:52.752000)

updates: Combined two stories about weight loss medication demand and advertising spending

  • ➔
  • ➔
Version 0.09 (2023-10-08 15:59:25.949000)

updates: The story has been expanded with additional details about the medications and the advertising spending.

  • ➔
Version 0.08 (2023-10-08 15:54:33.507000)

updates: Increased focus on advertising spending by drug manufacturers

  • ➔
Version 0.07 (2023-10-08 15:51:46.175000)

updates: Incorporated additional details about the impact of weight loss injections on food producers

  • ➔
  • ➔
Version 0.06 (2023-10-08 15:51:17.397000)

updates: Incorporated information about Nestle shares and investor concerns

  • ➔
Version 0.05 (2023-10-08 15:50:18.020000)

updates: Incorporated information about the impact of weight loss medication on Walmart food sales

  • ➔
  • ➔
  • ➔
Version 0.04 (2023-10-08 15:48:53.439000)

updates: Added information on the impact of weight loss medication on the aviation industry and potential cost savings for airlines

  • ➔
  • ➔
Version 0.03 (2023-10-08 15:07:44.971000)

updates: Incorporated information about comparing Wegovy and Ozempic

  • ➔
  • ➔
Version 0.02 (2023-10-05 05:57:22.684000)

updates: The new input provides information on the economic benefits of Wegovy in Denmark and its impact on Novo Nordisk's share price and the Novo Nordisk Foundation's record profits.

  • ➔